Johnson & Johnson in $30bn swoop on Actelion to plug looming revenue hole

Johnson & Johnson in $30bn swoop on Actelion to plug looming revenue hole

Johnson & Johnson unveiled the biggest deal in its 130-year history as the world’s largest healthcare company sought to revive its flagging pharmaceuticals division with a $30bn take­over of Swiss drugmaker Actelion. The acquisition ends a long quest by Alex Gorsky, J&J chief executive, to boost growth at the company’s drugmaking unit, and comes after…

This content is for Standard & Premium Digital Subscribers only.
Log In Subscribe

Related Posts